Search results for "Platelet"

showing 10 items of 786 documents

Translocation of cdk2 to the nucleus during G1-phase in PDGF-stimulated human fibroblasts.

1997

We studied the subcellular distribution of cdk2 in synchronized, PDGF-stimulated human fibroblasts (FH109). After contact inhibition and serum depletion, more than 95% of FH109 cells were arrested in G0/G1-phase. PDGF-AB led to a 16-fold increase in proliferation compared with untreated cells. Cell cycle progression was studied by flow cytometric analysis, [3H]thymidine incorporation, and phosphorylation of the retinoblastoma gene product, pRB. Using Western blot analysis after subcellular fractionation, we revealed that after PDGF stimulation the phosphorylated (Thr 160), i.e., activated, form of cdk2 (33 kDa) first appeared in the nucleus at late G1-phase and persisted throughout until to…

CytoplasmFluorescent Antibody TechniqueProtein Serine-Threonine KinasesmedicineCDC2-CDC28 KinasesHumansCells CulturedCell NucleusPlatelet-Derived Growth FactorbiologyKinaseCyclin-dependent kinase 2Cyclin-Dependent Kinase 2G1 PhaseContact inhibitionBiological TransportCell BiologyCell cycleFibroblastsMolecular biologyCyclin-Dependent KinasesCell biologyCell CompartmentationCytosolmedicine.anatomical_structurebiology.proteinCell fractionationNucleusPlatelet-derived growth factor receptorCyclin-Dependent Kinase-Activating KinaseExperimental cell research
researchProduct

A germline mutation in the platelet-derived growth factor receptor beta gene may be implicated in hereditary progressive mucinous histiocytosis.

2020

DermatologyBiologymedicine.diseaseSkin DiseasesReceptor Platelet-Derived Growth Factor betaHistiocytosisGermline mutationChronic diseaseHereditary progressive mucinous histiocytosisChronic DiseaseCancer researchmedicinePlatelet-Derived Growth Factor Receptor BetaHumansPlatelet-Derived Growth Factor BetaReceptorGeneHistiocytosisGerm-Line Mutation
researchProduct

In vitro and in vivo characterization of a new organic nitrate hybrid drug covalently bound to pioglitazone.

2014

<b><i>Background/Aims:</i></b> Organic nitrates represent a group of nitrovasodilators that are clinically used for the treatment of ischemic heart disease. The new compound CLC-3000 is an aminoethyl nitrate (AEN) derivative of pioglitazone, a thiazolidinedione antidiabetic agent combining the peroxisome proliferator-activated receptor γ agonist activity of pioglitazone with the NO-donating activity of the nitrate moiety. <b><i>Methods:</i></b> In vitro and in vivo characterization was performed by isometric tension recording, platelet function, bleeding time and detection of oxidative stress. <b><i>Results:</i></…

DrugBlood PlateletsMaleBleeding TimePlatelet Aggregationmedia_common.quotation_subjectVasodilator Agentsmedicine.disease_causeMitochondria Heartchemistry.chemical_compoundNitrateFibrinolytic AgentsIn vivomedicineAnimalsHumansHypoglycemic AgentsRats WistarAortamedia_commonPharmacologyNitratesPioglitazoneChemistryGeneral MedicineReactive Nitrogen SpeciesIn vitroOrganic nitratesMice Inbred C57BLVasodilationBiochemistryCovalent bondVasoconstrictionThiazolidinedionesReactive Oxygen SpeciesPioglitazoneOxidative stressmedicine.drugPharmacology
researchProduct

Could resveratrol be a useful drug for the treatment of malignant hemopathies?

2013

Resveratrol is a poly-phenol with many beneficial effects: not only as an antioxidant, anti-inflammatory, and antiatherogenic agent, as well as a platelet aggregation inhibitor, but also as an antiproliferative and proapoptotic factor in various types of cancers. There are reviews about the mechanisms responsible for its effects in leukemia and lymphomas, emphasizing the chemosensitizing role of resveratrol, which allows overcoming the multidrug resistance of cancers. The action of resveratrol occurs preferentially on leukemic cells, and not on the normal ones. In addition, it is one of the few drugs that act on leukemic stem cells. If experimental results are promising, its application in …

DrugCancer Researchmedicine.medical_treatmentmedia_common.quotation_subjectAntineoplastic AgentsPharmacologyResveratrolAntioxidantsPatents as Topicchemistry.chemical_compoundNeoplasmsDrug DiscoveryStilbenesmedicineHumansPharmacology (medical)Antiatherogenic agentmedia_commonbusiness.industryGeneral Medicinemedicine.diseaseAntineoplastic Agents PhytogenicBioavailabilityLeukemiaOncologychemistryResveratrolHematologic NeoplasmsPlatelet aggregation inhibitorDrug Therapy CombinationStem cellbusinessAdjuvantRecent patents on anti-cancer drug discovery
researchProduct

Number of drugs used in secondary cardiovascular prevention and late survival in the population of Valencia Community, Spain.

2019

Abstract Background Drug treatment for secondary prevention of cardiovascular disease is recommended by guidelines, but it is not always followed in real life. This study wanted to assess the size of this gap and its impact on mortality in subjects after a cardiovascular event (MACE). Methods Patients with any of MACE in the period from January 1st 2011 to December 31st 2013, and more than one year of follow-up were selected from population of the Valencian Community. Drugs for secondary prevention were antiplatelets, renin-angiotensin system blockers and statins. Assessment of treatment was performed one year after the initial event. Mortality risk was assessed using Cox by the number of d…

DrugMalemedicine.medical_specialtyMedication Therapy Managementmedia_common.quotation_subjectmedicine.medical_treatmentPopulationMyocardial InfarctionAngiotensin-Converting Enzyme InhibitorsDisease030204 cardiovascular system & hematologyRevascularizationRisk Assessment03 medical and health sciencesAngiotensin Receptor Antagonists0302 clinical medicineInternal medicinemedicineSecondary PreventionHumans030212 general & internal medicineMyocardial infarctioneducationStrokemedia_commonAgededucation.field_of_studybusiness.industryConfoundingmedicine.diseaseSurvival AnalysisProfessional Practice GapsStrokeSpainFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessMacePlatelet Aggregation InhibitorsInternational journal of cardiology
researchProduct

Biowaiver monograph for immediate-release solid oral dosage forms: acetylsalicylic acid.

2012

A biowaiver monograph for acetylsalicylic acid (ASA) is presented. Literature and experimental data indicate that ASA is a highly soluble and highly permeable drug, leading to assignment of this active pharmaceutical ingredient (API) to Class I of the Biopharmaceutics Classification System (BCS). Limited bioequivalence (BE) studies reported in the literature indicate that products that have been tested are bioequivalent. Most of the excipients used in products with a marketing authorization in Europe are not considered to have an impact on gastrointestinal motility or permeability. Furthermore, ASA has a wide therapeutic index. Thus, the risks to the patient that might occur if a nonbioequi…

Drugmedia_common.quotation_subjectPharmaceutical ScienceAdministration OralBiological AvailabilityPharmacologyBioequivalenceMarketing authorizationDosage formDrug StabilityFibrinolytic AgentsAnimalsHumansCyclooxygenase Inhibitorsmedia_commonActive ingredientAspirinChemistryAnti-Inflammatory Agents Non-SteroidalBiopharmaceutics Classification SystemSolubilityTherapeutic EquivalencyPlatelet aggregation inhibitorCaco-2 CellsFibrinolytic agentPlatelet Aggregation InhibitorsTabletsJournal of pharmaceutical sciences
researchProduct

Tendencia en la utilización de antiagregantes en la Comunidad Valenciana (2000-2005)

2007

Beatriz Román Llamosí, Rocío Broseta Solaz, Joan Quiles Izquierdo y Amalia Úbeda Pascual (Amalia.Ubeda@uv.es) Los antiagregantes plaquetarios son fármacos básicos para la prevención de enfermedades isquémicas arteriales. El objetivo de este trabajo es conocer la evolución de su utilización en Atención Primaria en la Comunidad Valenciana durante el periodo 2000-2005. Métodos: Estudio descriptivo del consumo de los antiagregantes plaquetarios (código ATC: B01AC) dispensados con cargo al Sistema Nacional de Salud en la Comunidad Valenciana en el ámbito de Atención Primaria. Datos expresados en dosis diarias definidas (DDD) por 1.000 habitantes y día. Resultados: En 2005 tres fármacos represent…

Drugmedicine.medical_specialtyArterial diseasemedia_common.quotation_subjectlcsh:MedicinePrimary careUNESCO::CIENCIAS MÉDICAS ::Salud públicaInternal medicineAntiagregantes plaquetarios:CIENCIAS MÉDICAS ::Salud pública [UNESCO]MedicineUtilización de medicamentosmedia_commonNational healthbusiness.industryIncidence (epidemiology)lcsh:Public aspects of medicineÁcido acetilsalicícicolcsh:Rlcsh:RA1-1270General MedicineClopidogrelClopidogrelSurgeryPlatelet aggregation inhibitorTriflusalbusinessAntiagregantes plaquetarios; Clopidogrel; Ácido acetilsalicícico; Utilización de medicamentosmedicine.drug
researchProduct

Role of the protein C receptor in cancer progression

2014

The hemostatic system plays pleiotropic roles in cancer progression by shaping the tumor microenvironment and metastatic niches through thrombin-dependent fibrin deposition and platelet activation. Expanding experimental evidence implicates coagulation protease receptors expressed by tumor cells as additional players that directly influence tumor biology. Pro-angiogenic G protein-coupled signaling of TF through protease activated receptor 2 and regulation of tumor cell and vascular integrins through ligation by alternative spliced TF are established pathways driving tumor progression. Our recent work shows that the endothelial protein C receptor (EPCR), a stem cell marker in hematopoietic, …

Endothelial protein C receptorTumor microenvironmentCD30Endothelial Protein C ReceptorBreast NeoplasmsReceptors Cell SurfaceHematologyBiologyStem cell markerArticleAntigens CDTumor progressionCancer stem cellDisease ProgressionTumor MicroenvironmentCancer researchAnimalsHumansFemalePlatelet activationBlood CoagulationProtease-activated receptor 2Signal TransductionThrombosis Research
researchProduct

Polynitroxylated hemoglobin-based oxygen carrier: inhibition of free radical-induced microcirculatory dysfunction.

1999

Reactive oxygen species have been identified as key mediators of leukocyte/endothelial cell interaction under various pathological conditions and diseases such as ischemia/reperfusion injury, inflammation, and after exposure to cigarette smoke. Consequently, antioxidants have been shown to successfully prevent the sequelae of these conditions, ranging from tissue infarction to atherogenesis. In this study we investigated whether, via its established superoxide dismutase-like activity, a novel polynitroxyl hemoglobin-based oxygen carrier (PNH), could affect the stimulation of leukocyte rolling and adhesion to endothelial cells in response to cigarette smoke. Using the dorsal skin fold chambe…

EndotheliumFree RadicalsInflammationLeukocyte RollingPharmacologyBiochemistryMicrocirculationHemoglobinsDouble-Blind MethodPhysiology (medical)CricetinaemedicineCell AdhesionLeukocytesAnimalsPlateletchemistry.chemical_classificationReactive oxygen speciesMesocricetusChemistryMicrocirculationSmokingmedicine.diseaseEndothelial stem cellOxygenmedicine.anatomical_structureImmunologyFemaleEndothelium Vascularmedicine.symptomReperfusion injuryFree radical biologymedicine
researchProduct

Lymphatic endothelial progenitors bud from the cardinal vein and intersomitic vessels in mammalian embryos.

2012

Abstract The lymphatic vasculature preserves tissue fluid balance by absorbing fluid and macromolecules and transporting them to the blood vessels for circulation. The stepwise process leading to the formation of the mammalian lymphatic vasculature starts by the expression of the gene Prox1 in a subpopulation of blood endothelial cells (BECs) on the cardinal vein (CV) at approximately E9.5. These Prox1-expressing lymphatic endothelial cells (LECs) will exit the CV to form lymph sacs, primitive structures from which the entire lymphatic network is derived. Until now, no conclusive information was available regarding the cellular processes by which these LEC progenitors exit the CV without co…

EndotheliumMesenchymegovernment.form_of_governmentRecombinant Fusion ProteinsImmunologyEmbryonic DevelopmentMice TransgenicBiologyBiochemistryMiceMicroscopy Electron TransmissionCell MovementVascular BiologymedicineAnimalsLymph sacsProgenitor cellEmbryonic Stem CellsHomeodomain ProteinsMice KnockoutBuddingMembrane GlycoproteinsCommon cardinal veinsTumor Suppressor ProteinsfungiCell BiologyHematologyAnatomyAdherens JunctionsCadherinsEmbryo MammalianCoronary VesselsCell biologyPlatelet Endothelial Cell Adhesion Molecule-1Lymphatic Endotheliummedicine.anatomical_structureLymphatic systemgovernmentsense organsEndothelium LymphaticBlood
researchProduct